Carnegie Capital Asset Management LLC bought a new stake in shares of Incyte Co. (NASDAQ:INCY – Get Rating) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,650 shares of the biopharmaceutical company's stock, valued at approximately $223,000.

Other institutional investors also recently bought and sold shares of the company. Parkside Financial Bank & Trust lifted its holdings in shares of Incyte by 91.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 447 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 213 shares during the last quarter. Ellevest Inc. lifted its holdings in shares of Incyte by 210.1% in the 1st quarter. Ellevest Inc. now owns 673 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 456 shares during the last quarter. CKW Financial Group lifted its holdings in shares of Incyte by 33.3% in the 1st quarter. CKW Financial Group now owns 800 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 200 shares during the last quarter. Tobam lifted its holdings in shares of Incyte by 53.3% in the 1st quarter. Tobam now owns 892 shares of the biopharmaceutical company's stock worth $71,000 after acquiring an additional 310 shares during the last quarter. Finally, Parallel Advisors LLC lifted its holdings in Incyte by 22.5% during the 1st quarter. Parallel Advisors LLC now owns 976 shares of the biopharmaceutical company's stock valued at $78,000 after buying an additional 179 shares in the last quarter. 94.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Guggenheim lowered shares of Incyte to a "neutral" rating in a report on Tuesday, August 9th. SVB Leerink raised their target price on shares of Incyte from $58.00 to $63.00 and gave the company an "underperform" rating in a research report on Wednesday, July 20th. Morgan Stanley cut their price objective on shares of Incyte from $77.00 to $76.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 3rd. Oppenheimer dropped their target price on shares of Incyte from $109.00 to $98.00 in a research report on Wednesday, August 3rd. Finally, StockNews.com raised shares of Incyte from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, August 30th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $84.92.

Insider Buying and Selling at Incyte

Incyte Trading Down 0.8 %

Shares of INCY opened at $66.89 on Friday. The company has a current ratio of 3.91, a quick ratio of 3.85 and a debt-to-equity ratio of 0.01. Incyte Co. has a 12-month low of $61.91 and a 12-month high of $84.86. The firm has a 50-day moving average price of $73.33 and a 200 day moving average price of $75.38. The firm has a market capitalization of $14.88 billion, a P/E ratio of 15.74, a P/E/G ratio of 1.09 and a beta of 0.66.

Incyte (NASDAQ:INCY – Get Rating) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.61 by $0.24. Incyte had a net margin of 28.46% and a return on equity of 13.02%. The firm had revenue of $911.40 million during the quarter, compared to analyst estimates of $818.25 million. During the same quarter in the prior year, the firm posted $0.65 earnings per share. Incyte's quarterly revenue was up 29.1% on a year-over-year basis. Sell-side analysts forecast that Incyte Co. will post 2.45 EPS for the current year.

About Incyte

(Get Rating)

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Further Reading

• Get a free copy of the StockNews.com research report on Incyte (INCY)
• Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
• MarketBeat: Week in Review 9/19 – 9/23
• Why Does Tesla Stock Remain Resilient?
• Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
• 2 Semiconductor Stocks To Watch For Reversals

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY – Get Rating).

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.